Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy

Eye

Volumn 23, Issue 1, 2009, Pages 108-111

  Ishikawa, K ^a   Honda, S ^a   Tsukahara, Y ^a   Negi, A ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bevacizumab; Proliferative diabetic retinopathy; Vitrectomy

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; FIBROSIS; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPHTHALMOSCOPY; POSTOPERATIVE COMPLICATION; VITRECTOMY;

EID: 58249102934     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702983     Document Type: Article

References (11)

1. Fong DS, Aiello LP, Ferris III FL, Klein R. Diabetic retinopathy. Diabetes Care 2004; 27(10): 2540-2553.
2. Joussen AM, Joeres S. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev Ophthalmol 2007; 39: 69-87.
3. Helbig H, Kellner U, Bornfeld N, Foerster MH. Vitrectomy in diabetic retinopathy: outcome, risk factors, complications. Klin Monatsbl Augenheilkd (Written In German) 1998; 212(5): 339-342.
4. Kramer I, Lipp HP. Bevacizumab, a humanized antiangiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007; 32(1): 1-14.
5. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113(10): 1695.e1-1695.e15.
6. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006; 26(6): 699-700.
7. Mason III JO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142(4): 685-688.
8. Luke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26(9): 999-1005.
9. Scott GI. Ocular complications of diabetes mellitus. Br J Ophthalmol 1953; 37(12): 705-715.
10. Beer PM, Wong SJ, Hammad AM, Falk NS, O'Malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006; 26(8): 871-876.
11. Gibran SK, Sachdev A, Stappler T, Newsome R, Wong D, Hiscott P. Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). Br J Ophthalmol 2007; 91(5): 602-604.